- In recognition of Carbapenem intermediate production, and iopromide production patent

- First successful development ofCoQ10 in Korea

- A female leader with passion and ability



Choi Soo Jin, Director of the Medicine Research Institute of Daewoong Pharmaceutical (President Lee Jong Wook), was selected by the Korea Chemical Societyas the winner of its Technical Advancement award. This award is given to scientists who have made an outstanding contribution to the industry, and is decided through a strict selection process. The awards ceremony will be held on the 14th at the 106th annual meeting of the Korea Chemical Society in Exco, Daegu.

So far, Director Choi has shown outstanding performance in a field where industrialization was once not plausible. She patented a method for creating an intermediate of carbapenem antibiotic, a first in Korea. It was patented in Japan in September this year. Based on this technology, Daewoong Pharmaceutical recently launched an antibiotic, Meropenem. Last August, she obtained a patent for iopromide, a contrast medium for CT, and the product will be released in the first half of next year.

Director Choi developed CoQ10 for the second time in the world, and for the first time in Korea. She is a female leader of Daewoong,with infinite passion and smooth leadership. She entered the company in 1995 as a researcher, and was promoted to executive manager this year, taking charge of global R&D projects by playing a pivotal role in installing research centers in India, China and the USA. She said "Daewoong ‘s corporate culture of nurturing excellent personnel without discriminating by grade or gender has been of great help." She plans to intensify Daewoong’s global R&D system by creating synergies between domestic and overseas research centers,while focusing on the development of new medicines.